Crisis? What Crisis?
External financing has proven indispensable for small biotech companies in the drug arena, with the majority of firms viewing it as essential for accelerated development. Where external capital is lacking, growth becomes more difficult, and innovation slows. The ‘new normal’ involves partnerships and licensing, especially in Europe, while the M&A wave is not building as fast as once predicted.
In this issue:
Industrial Biotech - (Bio)economy 2.0
For years, policies promoting industrial production modelled on naturallyoccurring cycles have been little more than a thin green veneer used by oil and chemistry multinationals. At the new forum Industria Biotec, companies presented both new ideas and long-ignored solutions that – in cooperation with politics – could help avert the looming gas and climate catastrophes.
Focus: Pharma Services - Determined to grow
Over 40,000 on-site visitors to the CPHI in Frankfurt have shown that the COVID-19 pandemic has had a positive impact on the (bio)-pharmaceutical sector. A new CPHI annual survey predicts how business will develop in the future, with prospects for CDMOs and CROs looking rosy.
Special: Biofairs Compass
PharmaPack Europe, AMR Conference, BIO-Europe Spring 2023, Swiss Biotech Day 2023, Connect in Pharma
Christian Nafe, CFO, leon-nanodrugs GmbH